Rein Therapeutics Inc.

RNTX

US00887A2042

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:53:00 2025-02-18 EST			5-day change	1st Jan Change
2.400 ^USD	-1.64%		+11.03%	+2.83%

01-13	Rein Therapeutics Inc.(NasdaqCM:RNTX) added to NASDAQ Composite Index	CI
01-13	Aileron Therapeutics, Inc. will Change its Ticker to RNTX from ALRN	CI

Aileron Therapeutics, Inc. will Change its Ticker to RNTX from ALRN

January 13, 2025 at 12:00 am

Effective January 13, 2025, Aileron Therapeutics, Inc. will change its Nasdaq Capital Market stock ticker symbol to RNTX from ALRN.

Latest news about Rein Therapeutics Inc.

Rein Therapeutics Inc.(NasdaqCM:RNTX) added to NASDAQ Composite Index	01-13	CI
Aileron Therapeutics, Inc. will Change its Ticker to RNTX from ALRN	01-13	CI
Aileron Therapeutics Changes Name to Rein Therapeutics	01-10	MT
Aileron Therapeutics, Inc. has Changed its Name to Rein Therapeutics, Inc	01-10	CI
Rein Therapeutics Inc.(NasdaqCM:RNTX) dropped from NASDAQ Composite Index	01-09	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-14	CI
Aileron Therapeutics, Inc. - Special Call	11-13
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	11-13	CI
Aileron Therapeutics, Inc. - Shareholder/Analyst Call	24-08-20
Aileron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-14	CI
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Index	24-06-30	CI
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Index	24-06-30	CI
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Growth Index	24-06-30	CI
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Growth Index	24-06-30	CI
Certain Warrants of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	24-06-17	CI
Certain Common Stock of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	24-06-17	CI
Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes	24-05-16	CI
Aileron Therapeutics, Inc. Announces Executive Changes	24-05-16	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-15	CI
Aileron Therapeutics Closes Direct Offering of Shares, Warrants	24-05-03	MT
Aileron Therapeutics, Inc. - Special Call	24-05-01
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	24-05-01	CI
Ladenburg Thalmann Adjusts Aileron Therapeutics Price Target to $19 From $9, Maintains Buy Rating	24-04-18	MT
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	24-04-15	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	24-04-15	CI

Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-25 - Q4 2024 Earnings Release (Projected)

More about the company